Metropolis Healthcare Ltd. (IN:METROPOLIS)
:METROPOLIS
Want to see IN:METROPOLIS full AI Analyst Report?
METROPOLIS Stock Chart & Stats
₹1929.70
-₹8.50(-0.42%)
At close: 4:00 PM EST
₹1929.70
-₹8.50(-0.42%)
Day’s Range― - ―
52-Week Range₹397.50 - ₹564.82
Previous CloseN/A
Volume139.28K
Average Volume (3M)3.90K
Market Cap
₹96.83B
Enterprise Value₹102.31B
Total Cash (Recent Filing)₹1.18B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)60.4
Beta0.78
Next Earnings
May 26, 2026EPS Estimate
2.57Next Dividend Ex-DateN/A
Dividend Yield0.21%
Share Statistics
EPS (TTM)2.34
Shares Outstanding207,327,770
10 Day Avg. Volume4,604
30 Day Avg. Volume3,901
Financial Highlights & Ratios
PEG Ratio4.05
Price to Book (P/B)5.90
Price to Sales (P/S)5.90
P/FCF Ratio35.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.86
Revenue Forecast (FY)₹18.71B
Bulls Say, Bears Say
Bulls Say
High Margins And ProfitabilitySustained high gross and operating margins indicate durable pricing power and efficient centralized lab processing. These structural advantages from scale and specialized testing support reinvestment in capacity, protect cash generation through industry cycles, and underpin long-term competitive resilience.
Strong Balance Sheet, Low LeverageA conservative capital structure with low leverage reduces solvency and refinancing risk while preserving flexibility for capex, network expansion, or M&A. The equity-heavy balance sheet provides a stable foundation to sustain multiyear investments in labs and technology without excessive financing strain.
Robust Cash Generation And ConversionStrong operating cash conversion and positive FCF growth signal that earnings reliably turn into spendable cash. This durable cashflow profile funds organic expansion, working capital for sample collection networks and technology, and reduces reliance on external capital for growth.
Bears Say
Moderate Net ProfitabilityDespite high gross and EBIT margins, net margin is only mid-single digits to low double digits, implying persistent downstream costs (SG&A, collections, commissions). This limits retained earnings and long-term ROE expansion unless structural operating costs or commission mixes are improved.
EPS Growth Lags Revenue GrowthA material gap between revenue and EPS growth suggests earnings dilution from investments, higher operating or financing costs, or margin compression in parts of the business. If structural, this disparity can constrain shareholder returns even as top line expands.
Franchise/collection Economics Cap Margin CaptureReliance on third‑party collection/franchise partners preserves scale but forces revenue-sharing and variable quality control. This structural model can cap margin expansion, introduce operational variability, and require ongoing investment in partner management and quality assurance.
Metropolis Healthcare Ltd. News
METROPOLIS FAQ
What was Metropolis Healthcare Ltd.’s price range in the past 12 months?
Metropolis Healthcare Ltd. lowest stock price was ₹397.50 and its highest was ₹564.82 in the past 12 months.
What is Metropolis Healthcare Ltd.’s market cap?
Metropolis Healthcare Ltd.’s market cap is ₹96.83B.
When is Metropolis Healthcare Ltd.’s upcoming earnings report date?
Metropolis Healthcare Ltd.’s upcoming earnings report date is May 26, 2026 which is in 27 days.
How were Metropolis Healthcare Ltd.’s earnings last quarter?
Metropolis Healthcare Ltd. released its earnings results on Feb 04, 2026. The company reported ₹2.338 earnings per share for the quarter, beating the consensus estimate of ₹2.235 by ₹0.103.
Is Metropolis Healthcare Ltd. overvalued?
According to Wall Street analysts Metropolis Healthcare Ltd.’s price is currently Overvalued.
Does Metropolis Healthcare Ltd. pay dividends?
Metropolis Healthcare Ltd. pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.21%. See more information on Metropolis Healthcare Ltd. dividends here
What is Metropolis Healthcare Ltd.’s EPS estimate?
Metropolis Healthcare Ltd.’s EPS estimate is 2.57.
How many shares outstanding does Metropolis Healthcare Ltd. have?
Metropolis Healthcare Ltd. has 207,327,770 shares outstanding.
What happened to Metropolis Healthcare Ltd.’s price movement after its last earnings report?
Metropolis Healthcare Ltd. reported an EPS of ₹2.338 in its last earnings report, beating expectations of ₹2.235. Following the earnings report the stock price went down -0.474%.
Which hedge fund is a major shareholder of Metropolis Healthcare Ltd.?
Currently, no hedge funds are holding shares in IN:METROPOLIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Metropolis Healthcare Ltd.
Metropolis Healthcare Limited provides diagnostic services in India. It offers clinical laboratory testing, and profiles and support services. The company provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, and youth and corporates. Its tests and profiles are used for prediction, early detection, diagnostic screening, confirmation, and/or monitoring of the disease. The company also offers corporate wellness and hospital laboratory solutions, as well as clinical research services. As of March 31, 2022, it operated 171 clinical laboratories, 9,000 pick-up points, and 704 assisted referral centers. The company was founded in 1980 and is headquartered in Mumbai, India.
Technical Analysis
HealthCare Global Enterprises Ltd.
―
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―